Cabot Corporation
NYSE:CBTChemicals - Specialty
+$0.96 today
- Market cap
- $3.80B
- Beta
- 0.83
- P/E (TTM)
- 16.3
- EPS (TTM)
- $5.48
- Dividend yield
- 2.04%
Volume 0.53M
Average 0.43M
CBT EBITDA
Earnings before interest, taxes, depreciation, and amortization; a proxy for operating profit before non-cash and financing charges.
Cabot CorporationNYSE: CBT
EBITDA · Q3 FY2026 · quarter ended Jun 2026
EBITDA declines year over year
Q3 FY2026 EBITDA of $148M fell 30.5% year over year, behind the -14.9% change in trailing-twelve-month EBITDA. Sequentially, it fell 22.1% from the prior quarter. Over 3 fiscal years it compounded at +13.9% a year.
Context
- EBITDA amounted to 21.4% of revenue in FY2025, up 2.3 pp from a year earlier.
- EBITDA increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether EBITDA reaches the consensus estimate from 4 analysts of $758.47M (-4.5%) for the fiscal year ending Sep 2026, a slowdown from the +4.3% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterJun 2026
- $148M-22.1% QoQ
- Last fiscal yearSep 2025
- $794M+4.3% YoY
- LTMJun 2026
- $690M-14.9% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | -30.5% | +8.8% | +39.3 pp |
| 1 year | +4.3% | -4.5% | -8.8 pp |
| 3-year CAGR | +13.9% | +2.5% | -11.4 pp |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
EBITDA history
USD · from the income statement
- Latest · FY2025
- 794M USD
- Year-over-year change
- +4.3%
- 4-year CAGR
- +6.6%
| Period | Period end | EBITDA | YoY change |
|---|---|---|---|
| FY2025 | 2025-09-30 | 794M | +4.3% |
| FY2024 | 2024-09-30 | 761M | +11.1% |
| FY2023 | 2023-09-30 | 685M | +27.6% |
| FY2022 | 2022-09-30 | 537M | -12.7% |
| FY2021 | 2021-09-30 | 615M | — |
EBITDA vs competitors
How CBT compares with its peers on the latest reported figures
- Peers report in different currencies, so EBITDA is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -14.9% is the 10th highest of 11, against a peer median of +12.4%.
- EBITDA amounts to 19.0% of revenue for CBT, versus a peer median of 16.7%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| FY2026 | ZAR 69.09B ZAR | +94.0% | +0.6% | 25.9% | |
| LTM Jun 2026 | $1.01B USD | +3.8% | -7.1% | 23.6% | |
| LTM Jun 2026 | $690M USD | -14.9% | +13.9% | 19.0% | |
| LTM Aug 2026 | $540.79M USD | +11.0% | +2.4% | 15.2% | |
| LTM Sep 2026 | $506.9M USD | +19.1% | +16.5% | 14.8% | |
| LTM Jun 2026 | $493.68M USD | +14.9% | +16.8% | 14.9% | |
| LTM Jun 2026 | $385M USD | +49.2% | -47.4% | 4.0% | |
| LTM Jun 2026 | $301.51M USD | +13.9% | +2.5% | 17.7% | |
| LTM Sep 2026 | $183.41M USD | +8.8% | +15.0% | 16.1% | |
| LTM Aug 2026 | $119.43M USD | +5.4% | +6.5% | 17.4% | |
| LTM Jun 2026 | -$300.15M USD | -303.2% | — | 39.6% | |
| Peer median (excluding CBT) | — | +12.4% | +2.5% | 16.7% | |
Competitors are the stored peer set for CBT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Sep 2021 | FY2022 Sep 2022 | FY2023 Sep 2023 | FY2024 Sep 2024 | FY2025 Sep 2025 |
|---|---|---|---|---|---|
| Revenue | 3.41B | 4.32B | 3.93B | 3.99B | 3.71B |
| Cost of Revenue | 2.61B | 3.44B | 3.09B | 3.03B | 2.77B |
| Gross Profit | 799M | 885M | 839M | 960M | 940M |
| Gross Margin | 23.4% | 20.5% | 21.3% | 24.0% | 25.3% |
| Research & Development | 56M | 55M | 57M | 63M | 59M |
| Selling, General & Admin | 289M | 258M | 253M | 283M | 260M |
| Operating Expenses | 345M | 496M | 313M | 346M | 319M |
| Depreciation & Amortization | 160M | 146M | 144M | 151M | 154M |
| EBITDA | 615M | 537M | 685M | 761M | 794M |
| EBITDA Margin | 18.0% | 12.4% | 17.4% | 19.1% | 21.4% |
| Operating Income | 454M | 389M | 526M | 614M | 621M |
| Operating Margin | 13.3% | 9.0% | 13.4% | 15.4% | 16.7% |
| Interest Income | 8M | 11M | 31M | 32M | 27M |
| Interest Expense | 49M | 56M | 90M | 81M | 76M |
| Other Income / Expenses | (45M) | (44M) | (70M) | (79M) | (49M) |
| Income Before Tax | 409M | 345M | 456M | 535M | 572M |
| Pre-Tax Margin | 12.0% | 8.0% | 11.6% | 13.4% | 15.4% |
| Income Tax Expense | 123M | 102M | (28M) | 111M | 196M |
| Net Income | 250M | 209M | 445M | 380M | 331M |
| Net Margin | 7.3% | 4.8% | 11.3% | 9.5% | 8.9% |
| EPS (Basic) | 4.36 | 3.65 | 7.79 | 6.79 | 6.07 |
| EPS (Diluted) | 4.34 | 3.62 | 7.73 | 6.72 | 6.02 |
| Weighted Avg Shares | 56.73M | 56.25M | 55.24M | 54.3M | 53.7M |
| Weighted Avg Shares (Diluted) | 56.8M | 56.9M | 56.5M | 55.7M | 54.2M |
Cabot Corporation
NYSE:CBT
Intrinsic Alpha fair value
Locked
Current Price
$74.03
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.